Skip to main content
ABT logo

ABT · Abbott Laboratories

Track ABT — free
$111.25 -0.02 (-0.02%) At close · Aug 14
Market Cap
$194.07B
Shares
1.74B

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$111.25 Open$111.49 Day$110.79–111.97 52W close$82.56–136.62 Avg vol 30d10.9M Short int22.6M · 1.3% float · 1.7d Short vol58% Last earningsJul 16, 2026 DataJan 2020–Aug 2026 Filing10-Q · Jul 28

Up next

Next earnings call
Oct 15, 2026 Est · unconfirmed · in 9 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
filed Jul 28, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Neutral
      SellHoldBuy
      Technical Buy Momentum Weak Sentiment Neutral Fundamentals Strong Quant / Vol Moderate
      Market backdrop VIX 14.3 · calm Equity put/call 0.52
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +4%
      above
      Price vs 50-day avg +14%
      above
      RSI (14) 73
      overbought
      MACD trend Positive
      52-week position 53%
      mid-range
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Weak
      1-month return +11%
      trailing
      6-month return −4%
      trailing
      YTD return −11%
      this year
      Relative strength −17%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $98 › 200d $107 — 200d above 50d
      Institutional flow Distributing
      -6% holders QoQ · +184 funds added
      Insider flow Distributing
      Net -$642.5K over 90 days · 100% sells
      Short interest Falling
      1.30% of float · ▼ -8.9% MoM · 1.7 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      2,912 holders — mid 3-yr range
      Squeeze score 57
      elevated · 0–100
      Fundamentals
      Strong
      Revenue growth +6%
      Y/Y
      EPS growth −51%
      Y/Y
      Free cash flow $7.4B
      Valuation P/E 31.2
      in line
      Buyback $5.6B
      remaining
      Balance sheet $4.4B
      net debt
      Quant / Vol
      risk profile
      Moderate
      Volatility 26%
      annualized · 1-yr
      Max drawdown −40%
      past year
      ATR 2.4%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Latest guidance · from the 8-K filed Jul 16, 2026
      full-year 2026
      Comparable sales growth 6.5% – 7.5%
      Adjusted diluted earnings per share Non-GAAP $5.45 – $5.60
      third-quarter 2026
      Adjusted diluted earnings per share Non-GAAP $1.38 – $1.46
      Prior guidance period ended · from the 8-K filed Jan 22, 2026
      Adjusted diluted earnings per share · first-quarter 2026 $1.12 – $1.18

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      1 · 3 · 3
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +4% Bullish
      Price vs 50-day avg
      +14% Bullish
      RSI (14)
      73 Bearish
      MACD trend
      Positive Bullish
      52-week position
      53% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bearish · 2 of 6
      Trend (MA cross) No cross
      50d $98 › 200d $107 — 200d above 50d
      Institutional flow Distributing
      -6% holders QoQ · +184 funds added
      Insider flow Distributing
      Net -$642.5K over 90 days · 100% sells
      Short interest Falling
      1.30% of float · ▼ -8.9% MoM · 1.7 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      2,912 holders — mid 3-yr range
      Price context
      position in its 52-week range
      Range low $83 Now $111 · 53% Range high $137
      vs 200-day avg +4% vs 50-day avg +14%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Versus peers

      Medical Devices — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      ABT
      Abbott Laboratories
      this stock
      $194.07B -11.2% +5.7% 31.2 1.3%
      SYK
      Stryker Corp
      $133.18B -3.5% +11.2% 36.0 2.2%
      MDT
      Medtronic plc
      $116.83B -5.0% +8.4% 24.5 1.4%
      BSX
      Boston Scientific Corp
      $75.11B -45.6% +12.5% 21.0 1.5%
      EW
      Edwards Lifesciences Corp
      $52.80B +7.4% +11.5% 52.6 1.7%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      2,912
      % held
      80.1%
      Net QoQ
      +3.4M sh
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      1,107
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      22.6M
      Days to cover
      1.7d
      Change
      -2.2M sh
      View
      Short Volume
      Short vol %
      58%
      As of
      Aug 14, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      177
      Value
      $16.7K
      As of
      Jul 10, 2026
      View
      Off-Exchange
      Off-exchange %
      53.1%
      Week of
      Jul 6, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$642.5K
      Buyers / Sellers
      0 / 1
      Buyers Sellers
      View
      Congressional Trades Sell
      Member
      Mike Kelly
      Amount
      $1.0K–$15.0K
      Traded
      Jul 17, 2026
      View
      Financials
      Financials
      Revenue (FY)
      $44.3B
      Net income (FY)
      $6.5B
      EPS diluted
      $3.72
      View
      Buybacks
      Remaining
      $5.6B
      View
      Filings
      SEC Filings
      Latest
      10-Q
      Filed
      Jul 28, 2026
      This year
      13
      View
      Proposed Sales
      Value
      $642.5K
      Shares
      5.9K
      Filed
      Aug 11, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Jul 16, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      ABT +3.2% +10.5% -3.5% +5.3% -11.2%
      SPY +0.4% +4.5% +13.8% +3.9% +13.9%
      vs SPY +2.8% +6.1% -17.3% +1.3% -25.1%

      Capital returns

      Latest dividend
      $0.63 / share · ex Jul 15, 2026
      Raised 6.8%
      Paid (TTM)
      $2.48 / share · 4 payouts
      Dividend yield (TTM, derived)
      2.23%
      Buyback program · as of Jun 30, 2026
      Authorized
      Spent (derived)
      Remaining
      $5.60B

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 1800 CUSIP 002824100 13F (30d) 2588 filings 2507 filers Visit website